Stockscreener 앱 받기
1.84
3.31%
0.03
시간 외 거래:
1.90
0.06
+3.26%
전일 마감가:
$1.81
열려 있는:
$2
하루 거래량:
9,724
Relative Volume:
1.32
시가총액:
$10.32M
수익:
$2.35M
순이익/손실:
$-2.56M
주가수익비율:
-4.1856
EPS:
-0.4396
순현금흐름:
-
1주 성능:
+1.70%
1개월 성능:
-2.09%
6개월 성능:
-19.40%
1년 성능:
+2.75%
1일 변동 폭
$1.84
$2.00
1주일 범위
$1.7334
$2.00
52주 변동 폭
$1.59
$5.96
이뮤론 Stock (IMRN) Company Profile
IMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IMRN | 1.84 | 10.32M | 2.35M | -2.56M | 0 | -0.4396 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
이뮤론 주식(IMRN)의 최신 뉴스
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® - GlobeNewswire Inc.
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron requests pre-IND meeting for IMM-529 with FDA filing | Daily Guardian - Daily Guardian Canada
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Immuron Surges On U.S. DoD Funding For Travelan Research - Yahoo Movies UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - MSN
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug - Stockhead
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed - Stockhead
45 Stocks Moving in Tuesday's Pre-Market SessionArbutus Biopharma (NASDAQ:ABUS), ACADIA Pharmaceutical - Benzinga
36 Stocks Moving in Monday's Pre-Market Session - Benzinga
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortf - Benzinga
58 Biggest Movers From YesterdayArbutus Biopharma (NASDAQ:ABUS), Acer Therapeutics Inc (OTC:ACER) - Benzinga
IMMURON LIMITED - ShareCafe
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
29 Stocks Moving In Wednesday's Mid-Day SessionBabcock & Wilcox (NYSE:BW), AstroNova (NASDAQ:ALOT) - Benzinga
35 Stocks Moving In Tuesday's Mid-Day SessionAyala Pharmaceuticals (OTC:ADXS) - Benzinga
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.27%
0.88%
자본화:
|
볼륨(24시간):